Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
Amy B. Heimberger, MD
Advertisement
Articles by Amy B. Heimberger, MD
Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.
Advertisement
Latest Updated Articles
Dr. Heimberger on the Variability of Responses in GlioblastomaPublished: June 25th 2021 | Updated:
Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune SuppressionPublished: November 21st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5